According to WHO, tuberculosis remained one of the most serious infectious diseases in 2024, claiming more than 1.2 million lives and affecting approximately 10.7 million people in the past year[1]. The WHO 2025 report states that progress in diagnosis, treatment and innovation has improved, but is still insufficient to achieve the goals of the End TB Strategy[1]. Global TB funding has stagnated since 2020; in 2024, only $5.9 billion was available for prevention, diagnosis and treatment, just over a quarter of the $22 billion per year target for 2027[1][5]. Funding for TB research reached $1.2 billion in 2023, about 24% of the target[1][5]. Modelling shows that long-term reductions in international donor support from 2025 onwards could lead to up to 2 million additional deaths and 10 million additional cases between 2025 and 2035, according to estimates cited in the report[1][6]. As of August 2025, there were 63 diagnostic tests in development, 29 drugs in clinical trials, and 18 candidate vaccines, 6 of which were in Phase 3, indicating an increase in innovative activity compared to 2015[1]. WHO and other institutions warn that interrupted or reduced funding threatens the gains made and call for sustained political commitment and investment[1][4].